[go: up one dir, main page]

MX2025001627A - Dispersiones solidas amorfas que contienen naporafenib - Google Patents

Dispersiones solidas amorfas que contienen naporafenib

Info

Publication number
MX2025001627A
MX2025001627A MX2025001627A MX2025001627A MX2025001627A MX 2025001627 A MX2025001627 A MX 2025001627A MX 2025001627 A MX2025001627 A MX 2025001627A MX 2025001627 A MX2025001627 A MX 2025001627A MX 2025001627 A MX2025001627 A MX 2025001627A
Authority
MX
Mexico
Prior art keywords
naporafenib
amorphous solid
solid dispersions
present
pharmaceutical compositions
Prior art date
Application number
MX2025001627A
Other languages
English (en)
Inventor
Oliver Graner
Cornelius Stephan Harlacher
Jennifer Claire Hooton
Raman Iyer
Vijay Sethuraman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2025001627A publication Critical patent/MX2025001627A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al campo de la farmacia, particularmente a una composición farmacéutica que comprende N-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2- (trifluorometil)isonicotinamida, o una sal farmacéuticamente aceptable de la misma. La presente invención también proporciona un proceso para preparar dichas composiciones farmacéuticas para administración oral y métodos de tratamiento con dichas composiciones farmacéuticas.
MX2025001627A 2022-08-10 2025-02-07 Dispersiones solidas amorfas que contienen naporafenib MX2025001627A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263370989P 2022-08-10 2022-08-10
PCT/IB2023/000477 WO2024033703A1 (en) 2022-08-10 2023-08-09 Amorphous solid dispersions comprising naporafenib

Publications (1)

Publication Number Publication Date
MX2025001627A true MX2025001627A (es) 2025-05-02

Family

ID=88236754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001627A MX2025001627A (es) 2022-08-10 2025-02-07 Dispersiones solidas amorfas que contienen naporafenib

Country Status (10)

Country Link
EP (1) EP4568655A1 (es)
JP (1) JP2025526729A (es)
KR (1) KR20250041176A (es)
CN (1) CN120076794A (es)
AU (1) AU2023323022A1 (es)
CA (1) CA3264293A1 (es)
IL (1) IL318900A (es)
MX (1) MX2025001627A (es)
TW (1) TW202408463A (es)
WO (1) WO2024033703A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
WO2024033703A1 (en) 2024-02-15
TW202408463A (zh) 2024-03-01
CN120076794A (zh) 2025-05-30
JP2025526729A (ja) 2025-08-15
KR20250041176A (ko) 2025-03-25
EP4568655A1 (en) 2025-06-18
AU2023323022A1 (en) 2025-02-20
CA3264293A1 (en) 2024-02-15
IL318900A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
EP4563150A3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
MX2011013164A (es) Forma de sosis farmaceutica para administracion oral de un inhibidor de la familia bcl-2.
PH12019502566A1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a] pyrimidine derivatives
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
EP4306113A3 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
CR20240514A (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2023012521A (es) Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
MX2025001627A (es) Dispersiones solidas amorfas que contienen naporafenib
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
TW201129557A (en) Pharmaceutical composition for oral administration
ZA202200331B (en) Naltrexone formulation
MX2024000084A (es) Compuesto de tiazololactama dimetil sustituido y uso de este.